A Phase 1/2, Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation
Latest Information Update: 06 Dec 2023
At a glance
- Drugs YL-15293 (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors Shanghai Yingli Pharmaceutical
- 17 Nov 2021 New trial record